Journal of Oral and Maxillofacial Surgery
Volume 66, Issue 4 , Pages 625-631 , April 2008

Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study

  • John H. Wessel, BS

      Affiliations

    • Third Year DMD Student, Harvard School of Dental Medicine, Boston, MA.
    • ,
  • Thomas B. Dodson, DMD, MPH

      Affiliations

    • Associate Professor, Department of Oral and Maxillofacial Surgery; Massachusetts General Hospital; and Consultant, Novartis Inc, East Hanover, NJ.
    • ,
  • Athanasios I. Zavras, DMD, DrMS

      Affiliations

    • Associate Professor and Director of Dental Public Health, Department of Oral Health Policy and Epidemiology; and Consultant Clinical Reviewer, Research Triangle Institute, Cary, NC.
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Zavras: Harvard School of Dental Medicine, Oral Health Policy and Epidemiology, 188 Longwood Avenue, REB217, Boston, MA 02115

References 

  1. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378
  2. Rosen LS. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol. 2002;29:28
  3. Kumar A, Loughran T, Alsina M, et al. Management of multiple myeloma: A systematic review and critical appraisal of published studies. Lancet Oncol. 2003;4:293–304
  4. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809
  5. Kyle RA. The role of bisphosphonates in multiple myeloma. Ann Intern Med. 2000;132:734
  6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  8. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med. 2005;34:120
  9. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83
  10. Zavras AI, Zhu S. Bisphosphonate treatment and risk of surgery of the jaw (Is it osteonecrosis?). J Oral Maxillofac Surg. 2006;64:917
  11. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol. 2006;134:620
  12. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol. 2005;24:945
  13. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:858
  14. Dimitrakipoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: A clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006;35:588
  15. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002;104:83
  16. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69:35
  17. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538
  18. Borissova AM, Tankova T, Kirilov G, et al. The effect of smoking on peripheral insulin sensitivity and plasma endothelin level. Diabetes Metab. 2004;30:147
  19. Whiteford L. Nicotine, CO and HCN: The detrimental effects of smoking on wound healing. Br J Community Nurs. 2003;8:S22
  20. Silverstein P. Smoking and wound repair. Am J Med. 1992;93:22S
  21. Millar WJ, Locker D. Smoking and oral health status. J Can Dent Assoc. 2007;73:155
  22. Albandar JM, Steckfus CF, Adesanya MR, et al. Cigar, pipe, and cigarette smoking as a risk factor for periodontal disease and tooth loss. J Periodontol. 2000;71:1874
  23. Childs S. Osteonecrosis. Orthop Nurs. 2005;24:295
  24. Smith D. Is avascular necrosis of the femoral head the result of inhibition of angiogenesis?. Med Hypotheses. 1997;49:497
  25. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94
  26. Goldwaser B. Risk factor assessment for the development of osteoradionecrosis. J Oral Maxillofac Surg. 2006;64:24

 This study was supported and funded by NIDCR (grant DE018143-01).

PII: S0278-2391(07)02130-1

doi: 10.1016/j.joms.2007.11.032

Journal of Oral and Maxillofacial Surgery
Volume 66, Issue 4 , Pages 625-631 , April 2008

Article Tools